ASCO26: Alicia Morgans, MD, MPH, ARACOG - Summary - MDSpire

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

Share

Objective:

To report findings on the cognitive effects of darolutamide compared to enzalutamide.

Approach:
  • Study Overview: Dr. Alicia Morgans presented findings from ARACOG at the ASCO26 conference.
Key Findings:
  • Dr. Alicia Morgans reported that darolutamide was associated with less decline in cognitive testing than enzalutamide.
Interpretation:

These findings may help guide treatment choice in patients.

Conclusion:

Original Source(s)

ASCO26: Alicia Morgans, MD, MPH, ARACOG

  • July 1, 2026

Related Content

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer